Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

K.J. Gotink; M.N. Rovithi; R.R. de Haas; R.J. Honeywell; H. Dekker; D. Poel; K. Azijli; G.J. Peters; H.J. Broxterman; H.M.W. Verheul

doi:https://doi.org/10.1007/s13402-015-0218-8

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

K.J. Gotink, M.N. Rovithi, R.R. de Haas, R.J. Honeywell, H. Dekker, D. Poel, K. Azijli, G.J. Peters, H.J. Broxterman, H.M.W. Verheul

Research output: Contribution to journal › Article › Academic › peer-review

43 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	119-129
Journal	Cellular oncology
Volume	38
Issue number	2
DOIs	https://doi.org/10.1007/s13402-015-0218-8
Publication status	Published - 2015

Access to Document

https://doi.org/10.1007/s13402-015-0218-8

Cite this

@article{c00af9daed1a4f499cea7c0b33758b87,

title = "Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib",

author = "K.J. Gotink and M.N. Rovithi and {de Haas}, R.R. and R.J. Honeywell and H. Dekker and D. Poel and K. Azijli and G.J. Peters and H.J. Broxterman and H.M.W. Verheul",

year = "2015",

doi = "https://doi.org/10.1007/s13402-015-0218-8",

language = "Undefined/Unknown",

volume = "38",

pages = "119--129",

journal = "Cellular oncology",

issn = "2211-3428",

publisher = "IOS Press",

number = "2",

}

TY - JOUR

T1 - Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

AU - Gotink, K.J.

AU - Rovithi, M.N.

AU - de Haas, R.R.

AU - Honeywell, R.J.

AU - Dekker, H.

AU - Poel, D.

AU - Azijli, K.

AU - Peters, G.J.

AU - Broxterman, H.J.

AU - Verheul, H.M.W.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.1007/s13402-015-0218-8

DO - https://doi.org/10.1007/s13402-015-0218-8

M3 - Article

C2 - 25665527

SN - 2211-3428

VL - 38

SP - 119

EP - 129

JO - Cellular oncology

JF - Cellular oncology

IS - 2

ER -